Search Site
Home >> Signaling Pathways >> DNA Damage/DNA Repair >> HDAC >> Belinostat (PXD101)
Related Products
Belinostat (PXD101)Hydroxamate-type HDAC inhibitor

Belinostat (PXD101)

Catalog No. A4096
Size Price Stock Qty
Evaluation Sample $28.00 In stock
10mg $75.00 In stock
50mg $230.00 In stock
100mg $350.00 In stock
200mg $590.00 In stock

Tel: +1-832-696-8203


Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

Belinostat (PXD101)

Biological Activity

Description Belinostat (PXD101) is a novel inhibitor of pan-HDAC with an IC50 value of 27 nM.
Targets pan-HDAC          
IC50 27 nM          

Belinostat (PXD101) Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Belinostat (PXD101) Molarity Calculator



Chemical Properties

Cas No. 414864-00-9 SDF Download SDF
Synonyms PXD-101, PXD 101, PX105684, PX-105684
Chemical Name (E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Canonical SMILES C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO
Formula C15H14N2O4S M.Wt 318.35
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request


Belinostat (also known as PXD101) is a novel and potent hydroxamate-type inhibitor of histone deacetylase (HDAC) that inhibits the activity of HDAC in Hela cell extracts with 50% inhibition concentration IC50 value of 27 nM. Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines. In the treatment of urothelial carcinoma cell lines, belinostat dose-dependently inhibits proliferation in 5637, T24, J82 and RT4 cells with IC50 values of 1.0 μM, 3.5 μM, 6.0 μM and 10 μM respectively; while, in prostate cancer cell lines, it inhibits cancer cell growth with IC50 values ranging from 0.5 to 2.5 μM.


Michael T Buckley, Joanne Yoon, Herman Yee, Luis Chiriboga, Leonard Liebes, Gulshan Ara, Xiaozhong Qian, Dean F Bajorin, Tung-Tien Sun, Xue-Ru Wu and Iman Osman. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. Journal of Translational Medicine 2007; 5:49

Giovanni Luca Gravina, Francesco Marampon, Ilaria Giusti, Eleonora Carosa, Stefania Di Sante, Enrico Ricevuto, Vincenza Dolo, Vincenzo Tombolini, Emmanuele A Jannini and Claudio Festuccia. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. International Journal of Oncology 40: 711-720, 2012

Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2(8):721-8.